You are on page 1of 9

Recent highlights in the development of new antiviral drugs

Erik De Clercq

Twenty antiviral drugs, that is about half of those that are penciclovir, idoxuridine and trifluridine are used (the
currently approved, are formally licensed for clinical use in the latter three only topically) in the treatment of herpes
treatment of human immunodeficiency virus infections simplex virus (HSV) and/or varicella-zoster virus (VZV)
(acquired immune deficiency syndrome). The others are used in infections; ganciclovir, valganciclovir, foscarnet, cidofovir
the treatment of herpesvirus (e.g. herpes simplex virus, and fomivirsen (the latter only by intravitreal injection)
varicella zoster virus and cytomegalo virus), hepatitis B virus, have proven useful in the treatment of cytomegalovirus
hepatitis C virus or influenza virus infections. Recent (CMV) infections in immunocompromised patients (i.e.
endeavours have focussed on the development of improved AIDS patients that have CMV retinitis). Following the
antiviral therapies for virus infections that have already proved progression of amantadine and rimantadine (matrix 2
amenable to antiviral drug treatment, as well as for virus protein blockers) onto the market, the neuraminidase
infections for which, at present, no antiviral drugs have been inhibitors zanamivir and oseltamivir have become avail-
formally approved (i.e. human papilloma viruses, adenoviruses, able for the therapy (and prophylaxis) of influenza virus
human herpesvirus type 6, poxviruses, severe acute respiratory infections. Ribavirin has been used (topically as an aero-
syndrome coronavirus and hemorrhagic fever viruses). sol) in the treatment of respiratory syncytial virus infec-
tions, and the combination of ribavirin with (pegylated)
Addresses interferon-a has received increased acceptance for the
Rega Institute for Medical Research, Katholieke Universiteit Leuven, treatment of hepacivirus (hepatitis C virus; HCV) infec-
Minderbroedersstraat 10, B-3000 Leuven, Belgium
Corresponding author: De Clercq, Erik (
There are, however, several other important virus infec-
tions for which no antiviral drugs have been developed;
Current Opinion in Microbiology 2005, 8:552–560 even for those that are amenable to antiviral drug therapy
This review comes from a themed issue on there is still considerable room for improvement in terms
Antimicrobials of higher potency and/or increased selectivity or safety. In
Edited by Christopher Walsh and Malcolm GP Page this review, I will highlight some of the most recent
approaches towards the treatment of human papilloma
Available online 24th August 2005
virus (HPV) infections, adenovirus infections, HSV and
1369-5274/$ – see front matter VZV infections, human herpesvirus type 6 (HHV-6)
# 2005 Elsevier Ltd. All rights reserved. infections, poxvirus infections, hepacivirus infections,
corona virus infections (i.e. severe acute respiratory syn-
DOI 10.1016/j.mib.2005.08.010
drome [SARS]), influenza virus infections, hemorrhagic
fever virus infections and HIV infections (AIDS).

Introduction Human papilloma virus infections
Of the 40 antiviral drugs that have been formally Although cidofovir, which is also known as (S)-1-(3-
licensed for clinical use [1], 20 are used in the treatment hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC;
of human immunodeficiency virus (HIV) infections Figure 1), is formally licensed only for the intravenous
(acquired immune deficiency syndrome; AIDS). The treatment of CMV retinitis in AIDS patients, ‘off label’ it
anti-HIV compounds fall into five categories: first, the has been used successfully in the systemic and topical
nucleoside reverse transcriptase inhibitors (NRTIs), zido- treatment of several other DNA virus infections, such as
vudine, didanosine, zalcitabine, stavudine, lamivudine, polyoma-, papilloma-, adeno-, herpes- and pox-virus [2].
abacavir and emtricitabine; second, the nucleotide Particularly striking are the effects that have been obtained
reverse transcriptase inhibitor, tenofovir disoproxil fuma- with cidofovir (topical gel application or direct intralesional
rate; third, the non-nucleoside reverse transcriptase inhi- injection) in the treatment of HPV-associated papilloma-
bitors (NNRTIs), nevirapine, delavirdine and efavirenz; tous lesions, such as hypopharyngeal and esophageal
fourth, the protease inhibitors (PIs), saquinavir, ritonavir, papilloma, laryngeal papilloma, recurrent respiratory papil-
indinavir, nelfinavir, amprenavir, lopinavir (combined at a lomatosis (in children), anogenital HPV infections (i.e.
4 to 1 ratio with ritonavir), atazanavir and fosamprenavir; condylomata acuminata), bowenoid papulosis (perianal
and fifth, the fusion inhibitor, enfuvirtide. Lamivudine intraepithelial neoplasia), cervical and vulvar intraepithe-
and adefovir dipivoxil have been approved for the treat- lial neoplasia grade III, recalcitrant warts (including plantar
ment of hepatitis B virus infections. Of the anti-herpes- warts), and other mucocutaneous HPV lesions that did
virus agents, acyclovir, valaciclovir, famciclovir, brivudin, not respond to conventional therapies [3]. In most of

Current Opinion in Microbiology 2005, 8:552–560

8:552–560 .sciencedirect. Recent highlights in the development of new antiviral drugs De Clercq 553 Figure 1 Structures of the compounds indicated in Current Opinion in Microbiology 2005. www.

sciencedirect. exquisitely active against VZV. 8:552–560 www. they are unlikely to enhance the toxicity of are generally self-limiting.4-diamino-6-[3-hydroxy-2-phosphonomethoxy)pro. This novirus replication. of its degradation product. activity. PMEG and cPr degradation of 5-fluorouracil).9]. although tumor suppressor proteins p53 and pRb (which are neu. HPV-infected cells [3]. This effect might be related drug of penciclovir) and brivudin (BVDU). (HPMPC) and HPMPA should be evaluated in the future for their potential to treat adenovirus infections in humans. the N7-substituted mase complex. poxy]pyrimidine (HPMPO-DAPy. Also. bicyclic furo(2. valaciclovir tained that cidofovir specifically ‘kills’ HPV-positive cells (the oral prodrug of acyclovir).30 -dideoxycytidine. adenovirus infections can be shown not to interfere with the dihydropyrimidine dehy- severe and life-threatening. BAY 57-1293 (Figure 1). i. S-2242. respectively) in patients that have herpes zoster or HSV-1 infections. Figure 1) have proved to be potent and selective inhibitors of the in vitro New anti-HSV agents that target the viral helicase–pri- replication of adenoviruses [4]. famciclovir (the oral pro- by the induction of apoptosis. methyl)purine S-2242 and the 20 . in that they inhibit only VZV replication and not the replication of any other viruses such as HSV. whereas no anti-adenovirus activity complex comprises three viral proteins — the HSV UL5. BILS 179BS and. allogeneic hematopoietic stem to the free pyrimidine base. BVDU can potentiate propyl-2. ase. Figure 1) and excess of 100 000. the ether lipid ester (i. a virtually complete and durable resolution of cation in vitro at significantly lower concentrations and with the lesions was achieved following the application of significantly higher selectivity indices than those noted for cidofovir (as a 1% gel or cream). Cf 1743 [Figure 1]) do not have this drawback. but in immunocompromised 5-fluorouracil for two reasons: first. are able to specifically induce apop. cules that interact with the formation of the HSV DNA Current Opinion in Microbiology 2005. These alovudine (30 -fluoro-20 . In addition to cidofovir.e. for 5-fluorouracil (which is a cytostatic agent used in the example 9-(2-phosphonylmethoxyethyl)guanine (PMEG. BVU.30 -dideoxythymidine. Cf 1369.30 -dideoxynucleoside were recently reported to have in vivo efficacy in animal analogues zalcitabine (20 . 50% inhibitory concentration against viral replication) in ylmethoxypropyl)adenine (HPMPA. like cidofovir.554 Antimicrobials these cases. acyclovir. potential for the treatment of VZV infections. With a In addition to cidofovir. Although the BCNAs have proven to be as active.e. Cf 1368. and. This by itself Also. such as the thiazolylphenyl derivatives acyclic nucleoside 2-amino-7-(1. and Cf 1742 and Adenovirus infections Cf 1743 are 10-fold more active against VZV than BVDU Adenovirus infections in immunocompetent individuals [6. was observed for several other antiviral compounds. the toxicity of 5-fluorouracil (through inhibition of dihy- which. ddC) and models of HSV-1 and HSV-2 infections [8. such UL-8 and UL52 gene products — which together unwind as ribavirin. The newly discovered PMEDAP are currently being investigated for their poten. A further extension of this approach involves the mole- these compounds were found to inhibit adenovirus repli. also known compounds appear to function by enhancing the affinity as FddT and FLT) were found to inhibit in vitro ade. Although the (compelling) evidence for the effectiveness Herpes simplex virus and varicella-zoster of cidofovir against HPV infections stems from in vivo virus infections observations in an increasing number of patients. they are not degraded patients and. its use is restricted to tralized by the oncoproteins E6 and . the latter was cell transplant recipients. 1293 is superior to all other compounds currently used for the treatment of HSV infections [10]. At present. HSV and/or VZV infections include acyclovir. penciclovir and brivudin the double-stranded viral DNA and generate the primer/ [4]. of the helicase–primase complex for the HSV DNA. ddC and FLT in both experi. Cf 1742 [Figure 1] and lesions. The latter is to the ability of cidofovir to restore the function of the only available in some European countries. cidofovir (HPMPC) drogenase that initiates the catabolism of 5-fluorouracil appears to be the only licensed antiviral drug that can be [6]. in vitro Standard antiviral drugs currently used in the treatment of experiments with HPV-infected keratinocytes have ascer. a key enzyme in the tosis in HPV-infected keratinocytes. templates for DNA synthesis by the viral DNA polymer- HPMPO-DAPy. dropyrimidine dehydrogenase. the parent compounds (HPMPC and HPMPA) [5]. It might be worthwhile to further examine HPMPA. a few other acyclic nucleoside selectivity index (ratio of 50% cytotoxic concentration to phosphonates such as (S)-9-(3-hydroxy-2-phosphon. the BCNAs offer an unprecedented (S)-2. treatment of certain cancers) because through the release Figure 1) and 9-(2-phosphonylmethoxyethyl)-N6-cyclo. there BVDU cannot be administered concomitantly with are several other acyclic nucleoside phosphonates.3-d)pyrimidine nucleoside analogues tial in the treatment of HPV-associated papillomatous (BCNAs. It has been claimed that the antiviral potency of BAY- mentally and clinically oriented studies.7]. hexadecyloxypropyl [HDP] validates the further pursuit of helicase–primase inhibi- and octadecyloxyethyl [ODE]) prodrugs of cidofovir tors for the treatment of HSV infections. BCNAs are extremely selective in their anti-VZV successfully used to treat adenovirus infections [3].6-diaminopurine (cPr PMEDAP. foscarnet. Figure 1). in particular. especially. and second.3-dihydroxy-2-propoxy.

and. with the exception of HHV-6 and HHV-7. cidofovir has other non-structural proteins such as the NS3-encoded shown high efficacy in protection of mice from a lethal NTPase–helicase and serine protease and the NS5B- respiratory infection of either vaccinia or cowpox. CMV423 must Hepacivirus infections (hepatitis C) be targeted at an event that follows viral entry but that The present therapy for chronic hepatitis C consists of precedes viral DNA replication. but this length of time might be reduced to 24 weeks The family of poxviridae encompasses orthopoxviruses for patients infected with HCV genotypes 2 or 3. valganciclovir.sciencedirect. ment of vaccinia and cowpox infections [20]. Protein–protein or intranasal (aerosolized) dose. agent targeted at a phosphoprotein encoded by the non- ogues (i. 8-methyladenosine and idoxuridine) structural NS5A gene of the HCV genome [25].e. it viral DNA polymerase and can be considered (following would be useful to have an orally active drug at hand that phosphorylation) as substrate analogues (except for fos. could be self-administered [18]. In as antiviral drugs. In particular. daily) [22. as well as in the treatment of the complications been formally approved for the treatment of HHV-6 of vaccinia that can arise in immunocompromised infections [12]. HHV-6 and HHV-7 [14]. significantly enhance inhibition of orthopoxvirus replica- ing HCMV). CMV423 was also found pegylated interferon (IFN)-a2a (180 mg. humans. 8:552–560 . vaccinia. orf) and mollusciviruses (e.23]. prophylaxis) and consist of ganciclovir. has been increasingly recognized as mised patients (reviewed by De Clercq [17]).6. However. They exhibit broad-spectrum anti. In this (e. In an outbreak of smallpox. developed as potential (oral) drugs for the prophylaxis lines. tion (i. HDP-CDV has also proven effective in the treatment of lethal We have recently discovered a new antiviral agent. which inhibits the inter. unlike for CMV infections. When given Their lack of activity against HHV-6 is owing to a single orally. and nucleotide analogues (including HPMPC [cidofovir] and HPMPO-DAPy) are effective in various animal mod.g.e. acyclovir. modulator. S2242. which acts as a pyrophosphate analogue).7. In addition to the NS5A gene product. vaccinia virus respiratory infections in mice [21]. act as non-nucleoside inhibitors of herpesvirus and treatment of variola virus infection (Figure 1) [18]. Cidofovir has demon- interactions constitute a new target for the design of strated high effectiveness in the treatment of dissemi- antiviral agents to be further explored for their potential nated progressive vaccinia in athymic-nude mice [16]. Several nucleoside anal. to a lesser extent. hexadecy- carnet.e. higher potency and lower cytotoxicity. more. variola. cowpox. These data an important pathogen in immunocompromised patients indicate that cidofovir will be effective in the therapy and (in which it might cause life-threatening complications). Therefore. ribavirin is assumed to act as an immuno- pox). HDP-CDV and ODE- lizine-1-carboxamide. cidofovir has been used successfully by both the topical and intravenous route in the treatment of orf and Human herpesvirus type 6 infections recalcitrant molluscum contagiosum in immunocompro- HHV-6. HDP-CDV and ODE-CDV were as effective as amino acid change in the conserved domain III of the cidofovir is when administered parenterally for the treat- HHV-6 DNA polymerase [13]. there are a few els of poxvirus infections [15]. after administration of a single systemic (intraperitoneal) action between UL-30 and UL42) [11]. DNA polymerases. once weekly) to inhibit total cellular protein tyrosine kinase activity. Current Opinion in Microbiology 2005. www. Further- CMV423 (2-chloro-3-pyridin-3-yl-5.8-tetrahydroindo. BP5. Recent highlights in the development of new antiviral drugs De Clercq 555 polymerase complex (i. monkeypox and camel. the 4-oxo-dihydroxyquino. valaciclovir. vaccinia and cowpox) in vitro [19]. as cidofovir is a phosphonate analogue it has and foscarnet. was concluded that CMV423 exerts its activity against This treatment regimen produces a sustained virologic HHV-6 through inhibition of a cellular process that is response in at least 50% of the patients infected with crucial in the early stage of viral replication and that might HCV genotype 1 and 2 (and 80% of the patients infected involve protein tyrosine kinase activity [14]. cidofovir However. loxypropyl-cidofovir (HDP-CDV) and octadecyloxy- ethyl-cidofovir (ODE-CDV) were designed and Another class of compounds. These alkyloxyalkyl esters of cidofovir were found to viral activity against most human herpesviruses (includ. The drugs clinically used against patients inadvertently inoculated with the smallpox vac- HHV-6 are the same as those used in CMV therapy (or cine (vaccinia) [17]. parapoxviruses (e.g. It combined with ribavirin (1000 or 1200 mg. like CMV. Com. Figure 1). even encoded RNA-dependent RNA polymerase (RdRp. which demonstrated CDV proved highly efficacious in a lethal mousepox potent and selective in vitro activity against all three human (aerosol ectromelia virus) model. prophylaxis of smallpox (variola) and related poxviruses in however. its anti- viral action appeared to be cell-dependent. further attesting the b-herpesviruses — CMV. whereas the IFN would act as an antiviral molluscum contagiosum virus). Patients infected with HCV genotype 1 should be treated for at least 48 weeks Poxvirus infections [24]. All these compounds are targeted at the limited oral bioavailability. CMV423 showed a in the oral therapy and prophylaxis of poxvirus infections. no compounds have humans. with another genotype of HCV). when administered orally. potential usefulness of other lipid prodrugs of cidofovir pared to ganciclovir and foscarnet.

much Coronavirus infections emphasis has been recently put on the chemotherapy There are several HCV proteins encoded by the SARS (and prophylaxis) of influenza virus infections. and it has been fusogenic mechanism of HIV is similar to that of SARS. in the past they did not gain wide CoV (as well as for other enveloped viruses. including acceptance. these inhibit the [39]. There is no shortage of small molecules Equally attractive as a target for the development of HCV that are active in the 1–10 mM concentration range [38]. particularly for amantadine. expression by type-1 pneumocytes. a variety of ‘old’ and ‘new’ compounds have RNA has been provided for the protease inhibitor BILN been reported to inhibit the in vitro replication of SARS- 2061 (Figure 1) [26]. now two years after its first sidered as a surrogate virus for HCV [27. Although ribavirin is active in vitro against the replication CoV S protein mediates infection of permissive cells by of influenza virus. There . blocking SARS-CoV infection. combined with the fact that no vaccination is available for the latter. The matrix (M2) hydrogen ion channel blockers aman- ciation with the SARS-CoV receptor ACE2 [34]. for example the NTPase/helicase and RNA repli- Proof-of-principle that compounds targeted at the NS3 case. thus. tadine and rimantadine have been used for many years for tion to ACE2. such a structural basis still has to be elaborated. Knowledge of the crystal structure of the SARS-CoV main Influenza virus has adopted a unique replication strategy: protease offers a solid basis for rational drug design of it uses one of its surface glycoproteins. and pegylated IFN-a was recently shown to reduce replication of BVDV with high efficiency [29]. three classes of compounds that could be targets for chemotherapeutic intervention: the spike (S) considered for this purpose: ribavirin. and a human monoclonal antibody to the S1 domain was found to neutralize SARS-CoV by blocking its asso.g. protease could reduce plasma concentrations of HCV Meanwhile. In addi. the SARS-CoV main protease (also known as the rimantadine. We have apparition (and subsequent disappearance). Highly selective but whether any of these molecules will prevent or antiviral agents targeted at the viral RNA replicase have suppress the infection in vivo remains to be established. the C-type lectin CD209L (also called the prophylaxis and therapy of influenza A virus infec- L-SIGN) was identified recently as a receptor for SARS. other viral (or cellular) protein-mediated processes [31]. amantadine and protein. these non-nucleo- side RdRp inhibitors are likely to be combined with the Influenza virus infections ‘nucleoside’ RdRp inhibitors. Given the persistent epidemics of influenza A strains albeit a relatively weak inhibitor of BVDV and HCV. to the extent that the they are not active against influenza B. only the neuraminidase inhibitors zanamivir virtide. mainly for the following reasons: they rapidly Ebola). and oseltamivir are practically available for the therapy and/or prophylaxis of influenza A and B virus infections. A 193-amino acid fragment of the aerosol formulation in patients (primarily young infants) S protein (that corresponds to amino acid residues 318– that are at (high) risk of bronchopneumonitis caused by 510) was found to block S protein-mediated infection respiratory syncytial virus infection. For other potential envisaged as targets for inhibitors of HCV replication.5-c]pyridine [also known as BPIP. inhibitors is the HCV RNA replicase. hemagglutinin Current Opinion in Microbiology 2005. might be a target for lead to the emergence of drug-resistant virus mutants. However. future treatment of HCV infections. a pestivirus that could be con. possibly. Should SARS re-emerge. 8:552–560 www. prophylaxis and early post-exposure management of dazo[4. coronavirus (SARS-CoV) that could be considered as in principle. tions. six-helix bundle formation). [33].556 Antimicrobials which is also known as RNA replicase) that could be SARS-CoV protease inhibitors [36]. express the SARS-CoV receptor angiotensin-converting it has been developed for inhalation as a small-particle enzyme 2 (ACE2) [32]. In the infected experimentally with SARS-CoV [40]. CoV when present in relatively high concentrations (1 mM) [37]. and oseltamivir (Figure 1). like ACE2. new congeners have been derived that attendant pulmonary damage in cynomolgus macaques act equally efficiently against HCV replication. avian influenza A strain H5N1. with regard to heptad repeat interactions and side effects on the central nervous system. it has not been actively pursued for the controlling the interaction of its S1 domain with cells that management of influenza virus infections in vivo. is H3N2 and H1N1 and the threat of a pandemic with the N4-hydroxycytidine [30]. An example of the latter. From this viral replication and excretion. CD209L. At present. targets. that they exert CoV (e. to decrease viral antigen class of compounds. Instead. it should be feasible to develop SARS-CoV fusion inhibitors analogous to enfu. Figure 1]) that SARS: IFN-a inhibits SARS-CoV replication in vitro act as ‘non-nucleoside’ RdRp inhibitors. based on a different structure–activ. and to reduce the ity relationship. pegylated form of IFN-a would be a logical choice for the prototype 5-[(4-bromophenyl)methyl]-2-phenyl-5H-imi. The SARS. been described to inhibit the replication of bovine viral diarrhoea virus (BVDV). the NTPase/helicase. Also.g. which is used for treatment of HIV [35]. perhaps the recently described a novel series of compounds (e. the RNA-depen. and the neuraminidase inhibitors zanamivir 3C-like protease).sciencedirect. dent RNA polymerase (RdRp) and.28]. demonstrated.

Also. they therefore decrease the requirement for antibiotics. nematode anticoagulant protein C2. When used prophylacti. a reduction in virus exerts its antiviral activity in vitro appears to be based on transmission to household or healthcare contacts. yellow fever and dengue). different approach towards the treatment of Ebola should be stockpiled to affront a potential influenza A virus infection is based on the use of a recombinant pandemic in the future. whether pegy. HIV has generated more efforts towards antiviral drug Congo and Hantaan) and filoviridae (i.e. efficacy.e. nistered as a single dose on the first or second day after tamivir [43]. target specific novel and Current Opinion in Microbiology 2005. For the treatment of Ebola (or Marburg) virus infections. Recent highlights in the development of new antiviral drugs De Clercq 557 (H).e. forcing the aminidase inhibitors block the release of newly formed RNA virus into gaining a lethal accumulation of errors.49]. Lassa. and in particular oseltamivir. including dengue Some compounds. ribavirin (Figure 1) bicides: they show marked stability at relatively low pH can be accredited with some efficacy in experimental and high temperatures for prolonged time periods. terminal sialic acid (N-acetylneuraminic acid). Neur. they www. development than any other virus. nomethoxy)alkoxy]-2. At present. new prophylaxis and/or therapy of flavivirus infections as they acyclic nucleoside phosphonates (i. Various mechanisms of action another surface glycoprotein. they significantly reduce the number of new cases S-adenosylhomocysteine hydrolase inhibitors (such as that have influenza. This strategy Hemorrhagic fever virus infections targets the disease process rather than viral replication The most important hemorrhagic fever viruses fall within [52]. (pre)clinical investigation target the same specific viral lated or not. and a inhibition of inosine 5’-monophosphate dehydrogenase reduction in the frequency and severity of complications [41. arenaviridae (i.51]. Rift Valley. DAPy and PMEO-DAPy [55]) and deoxythreosyl nucleo- tal flavivirus encephalitis model in severe combined side phosphonates (i. which can the Ebola virus-infected animals [50. vaginal) microbicides. A totally be more conveniently administered as oral capsules. Crimean. Marburg). the plant lectins (i. IFN-a.54]. For flaviviruses (such as The benefits offered by the neuraminidase inhibitors are yellow fever) and paramyxoviruses (such as parain- substantial. and prob- (H1N1) virus [44]. Gua. Zanamivir and oseltamivir are both able to infection. they lead to a fluenza). Although resistance to neuraminidase carbocyclic 3-deazaadenosine and 3-deazaneplanocin inhibitors can develop [42]. also almost all the mice against a lethal Ebola virus infection. the 6-[2-(phospho- decrease virus-induced morbidity (paralysis) and mortal.e. In recent years.e. and would. and IFN inducers. cally. we have witnessed the development of novel approaches as Prospects for the therapy of flavivirus infections are not well as newly emerging (candidate) drugs for anti-HIV overwhelming [37]. virus. offer an appreciable potential for the viral proteins. but it remains to be demonstrated anilide UC-781 are being actively pursued as topical whether or not this antisense approach also offers in vivo (i. to cleave have been proposed to explain the antiviral activity of off the terminal sialic acid of the host cell receptor. and against Lassa fever [37]).e. has been described to inhibit the replica- tion of several RNA viruses in vitro. a potent inhibitor of tissue factor-initiated blood coagulation. neuraminidase.48]. (such as sinusitis and bronchitis). Ebola.41]. such as poly(I)poly(C) proteins as the licensed compounds. such as cyanovirin-N and thiocarbox- virus types 1–4 [46]. phosphonomethyldeoxythreosyl- immunodeficient mice [45]. According to this hypothesis. Another approach. The most fascinating of these is the theory of allowing the virus particles to leave the cells after the ‘error catastrophe’ [47. Figure 1) might be worth pursuing: even when admi- naturally occurring resistance to either zanamivir or osel. virus particles.e.4-diamino pyrimidines PMPO- ity (caused by progressive encephalitis) in an experimen. cellular uptake. ribavirin would act as an RNA virus mutagen. based adenine [PMDTA] and -thymine [PMDTT]. be effective against the 1918 pandemic influenza A and this protective effect was accompanied. the families of the flaviviridae (i. to bind to the target cell receptor. Zanamivir. thus preventing their further spread to This error catastrophe has been shown only with polio- other host cells. which must be taken by ably mediated. 8:552–560 . in theory. the predominant mechanism by which ribavirin reduction in illness in 1–2 days. which contains a animal models as well as in humans (in the latter case. 3-deazaneplanocin A was found to protect block influenza A and B viruses. bunyaviridae (i. or target cellular proteins [54]. Machupo. there is no evidence of A. Junin. Ribavirin has only weak activity therapy [53. Also. The compounds that are currently under against flaviviruses.e. viral replicative cycle has been completed [37. When used therapeutically. by an enhanced production of IFN in (oral) inhalation. Figure 1) on the conjugation of phosphorodiamidate morpholino [56] have been described as potent and selective anti- oligomers with arginine-rich peptides to increase their HIV agents. Human immunodeficiency virus infections narito and Sabia). it has not been demonstrated with other RNA viruses such as HIV or HCV. Galanthus nivalis agglutinin and Hippeastrum hybrid agglutinin) represent potential candidate anti-HIV micro- For arenaviruses and bunyaviruses.sciencedirect. ribavirin.

irrespective of whether or not they are currently amen. De Clercq E. 2005. toxi. R-278474 highlights the important require. a novel class of herpesvirus antiviral agents. Hendrix M. 4-oxo-dihydroquinolines. Kibler P. Biochem Pharmacol 2004. Faucher AM. Coen DM: Identification of a small molecule able to antiviral therapy. 191:396-399. 77:1868-1876. Hewlett G. both present and future. 30:115-133. Betz UA. Eckenberg P. 11. De Clercq E: Efficacy of cidofovir in a murine model of disseminated progressive I am grateful to Christiane Callebaut for her invaluable editorial assistance. high oral bioavail- 9. Current Opinion in Microbiology 2005. 67:325-336. Brideau RJ. De Clercq E: Highly potent and selective inhibition of varicella- zoster virus replication by bicyclic furo[2. Hargrave KD. antiviral strategies for the management of cytomegalovirus DNA polymerases confer resistance to SARS. Neyts J: Therapeutic potential of nucleoside/ are also reviewed. including therapy. McGuigan C. Hendrix M. Rev Med Virol 2004. minimal side Schneider U. the  of special interest  of outstanding interest virus acquires resistance mutations in the gp120 glyco- protein that are predominantly located at the N-glycosy- 1. Hostetler KY. Thomsen DR. Possible strategies for the prevention and treatment of Bousseau A. Neyts J. De Bolle L. Ciesla SL. Beadle JR. of HHV-6 potential of oral cidofovir prodrugs for the prophylaxis infections. crystallographers. Kleymann G. which shows activity 6. De Clercq E: Antiviral drugs in current clinical use. adefovir. Bender W. Antimicrob Agents Chemother 2002. De Clercq E. molecular modellers. Andrei G. of DNA virus and retrovirus infections. Snoeck R. developed for the treatment of HIV infections (AIDS) 15. selective hemorrhagic fever virus infections are . others [60]. Antimicrob Agents Chemother virologists. De Clercq E: Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Y181C) HIV-1 strains at sub-nanomolar concentrations. and therapy of poxvirus infections. De Clercq E: Potential of acyclic nucleoside phosphonates in propensity to deplete the viral envelope of its glycan the treatment of DNA virus and retrovirus infections. Zhang Y. 1:21-43. Knechtel ML. Naesens L: Potent. As a final highlight in the search for new anti-HIV agents. among 8. evolution starting from TIBO R-86183 in 1987 has yielded compound R-278474. De Clercq E: Clinical potential of the acyclic nucleoside phosphonates cidofovir. Otto M. Balzarini J. Simoneau B. Homa FL: Amino acid changes within conserved therapeutic approaches. vaccinia. 46:1766-1772. and the importance of having neuraminidase inhi. analytical chemists and pharmacists. Antimicrob Agents Chemother 2004. Clin Microbiol Rev 2005. 49:1081-1086. Naesens L. in vitro) of HIV to Hippeastrum hybrid agglutinin or to Galanthus nivalis agglutinin. Kleymann G. 16:569-596. 49:1010-1016. Rübsamen- In recent years. Cui C. Nat Med 2002. bitors at hand to affront future influenza virus epidemics. Wan WB. Gustin KM. Van Lommel A. and they prevent References and recommended reading entry of HIV into its target cell [57]. Andrei G. 14. New helicase–primase inhibitors as drug candidates for the treatment of herpes simplex disease. ability (allowing once-daily administration). can now be claimed to be (one of) the most potent anti- 5. Holý A. topical microbicides. published within the annual period of review. for HCV region III of the herpes simplex virus and human infections. Sienaert R. Antimicrob over a period of 17 years. Med Res Rev 2003. led to the identification of what Agents Chemother 2005.: effects. 12. 23:253-274. VZV and HHV-6 infections. Bolger G. Lenaerts L. Andrei G. and the and cell-mediated inhibition of human herpesvirus 6 at an many new (candidate) antiviral drugs that have been early stage of viral replication by the non-nucleoside compound CMV423. nucleoide analogues against poxvirus infections. Balzarini J. Cordingley MG: Herpes simplex ments of novel anti-HIV drugs: high antiviral potency virus helicase–primase inhibitors are active in animal models of human disease. type that can no longer escape the immune surveillance of 3. Wathen MW. De Clercq E. The discovery of R-278474 emanated from a coordinated Snoeck R: Susceptibilities of several clinical varicella-zoster multidisciplinary effort that involved medicinal chemists. Grygon CA. Fischer R. and therapy. due to their 2. 4. Acknowledgements 16.3-d]pyrimidine against both wild-type and NNRTI mutant (K103N + nucleoside analogues.sciencedirect. Nat Med 2002. Pilger BD. Rev Anti Infect Ther 2003. Expert shield [59]. against wild-type and mutant viruses. Liuzzi M. HSV. De Clercq E: Update on human lomatous lesions. Verbeken E. 48:2267-2273. and tenofovir in treatment the host. I have also discussed 13. 18:217-245. 11:647-654. future prospects for the treatment of  herpesvirus 6 biology. Hopkins TA. virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. considerable progress has been made Waigmann H: Potent in vivo antiviral activity of the herpes simplex virus primase–helicase inhibitor BAY 57-1293. clinical features. and ease of synthesis and formulation. Pevzner V et al. Oien NL. Hartline CB. J Clin Virol lation (asparagine) sites [58]. 8:392-398. plant lectins might. De Bolle L. J Infect Dis 2005. Leyssen P. Handke G.558 Antimicrobials directly interact with the viral envelope. Betz UA. adenovirus. towards the treatment of a wide variety of virus infections. and the Comprehensive review on all aspects. This chemical nucleoside phosphonates: activity against adenovirus replication in vitro. Upon prolonged Papers of particular interest. Conclusions 10. 7. J Virol 2003. I would like to cite the multidisciplinary approach that. Highlighted in this review are: that inhibits herpes simplex virus DNA polymerase subunit the potential of cidofovir and other acyclic nucleoside interactions and viral replication. Naesens L. 8:552–560 www. Fischer R. Clin Microbiol Rev 2003. phosphonates for the treatment of HPV-associated papil. Crute JJ. Roy C. Kern ER: Ether lipid-ester prodrugs of acyclic which is also known as rilpivirine [60]. In addition to their role as 2004. HIV agents ever discovered: the NNRTI R-278474. Van Beers D. 8:386-391. cologists. 14:289-300. have been highlighted as: exposure (in cell culture. force the virus to convert to a gp120 pheno. Snoeck R. Chem Biol 2004.

virus infection. Xiao G. N Engl J Med 2002. Häussinger D. Klimov A. 47:2264-2272. Ma S-H. Chen Y. Gil L. O’Boyle DR II. Drosten C. Huang CY-H. 2001. 123:1061-1069. Moore MJ. Balasingam S. De Clercq E: Antivirals and antiviral strategies. 47:777-782. Tashiro M. Vasilieva N. Colonno R. Hostetler KY. 1:209-218. Eickmann M. Hayden F. Yang M.: The crystal structures of severe acute respiratory Kern ER: Oral treatment of cowpox and vaccinia virus syndrome virus main protease and its complex with an infections in mice with ether lipid esters of cidofovir. 140:346-355. coronavirus. Antimicrob Agents Chemother 2004. Ansari IH. Proc Natl Acad Sci USA 2003. Zambon M: Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates 27. Poynard T. Liu Y. Fouchier RA. Dhumeaux D et al. Ye S. Jones SM. Yang H. Wu D. 32. Lou Z. J Infect Dis 2004. Antimicrob Iversen PL. 44. Shiraishi K. Int J Antimicrob Agents 2004. Somasundaran M. Becker S. Dreher TW.sciencedirect. Stein DA: Inhibition of dengue virus serotypes 1 to 4 Agents Chemother 2003. Crotty S. Manns M. Anderson PC. 426:186-189. Farzan M: A 193-amino 49. Ramesh M. Bailey M. Hostetler KY: Design and development of oral drugs (SARS) coronavirus by a human mAb to S1 protein that  for the prophylaxis and treatment of smallpox infection. Dienstag J. Beaulieu P. Gastroenterology 2002. De Clercq E: Strategies in the design of antiviral drugs. 1:867-881. Lee WM. Reddy KR. 97:7981-7986. Balan V. Keith K. Proc Natl Acad Sci USA 2000. in Vero cell cultures with morpholino oligomers.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C 39. Feldmann H: Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-a. Nat Rev 25. repeat 1 and 2 regions in spike protein of SARS-associated Hostetler KY: Enhanced inhibition of orthopoxvirus replication coronavirus: implications for virus fusogenic mechanism and in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Rimmelzwaan response in genotype-1-infected patients with chronic  GF. J Virol 2005. Wu C-Y. Xiong H. Painter GR. inhibition of IMP dehydrogenase. Moore MJ. Donis R. Andino R: RNA virus error catastrophe: Angiotensin-converting enzyme 2 is a functional receptor for direct molecular test by using ribavirin. De Clercq E. Cameron CE. Cameron DR. Harden E. Bodenheimer H Jr. Matthews LJ. Murakami A. Jan J-T. Wong SK. Hsu H-H. Carosi G. Smith C. Sakai-Tagawa Y. Whitaker T. Hernandez-Santiago BI. Tan SL. Leyssen P. 47:244-254. 101:10012-10017. Brik A et al. Neyts J: Interferons. Sette H Jr. Beadle JR. 1:13-25. 46:991-995. Niu J. Pause A. Tamin A. Shiffman ML. Neuraminidase inhibitors (zanamivir and/or oseltamivir) should be made available (stockpiled) for prophylactic and therapeutic use in case of an 29. Pevear DC. Abrignani S. Mak C. Li W. Ströher U. Nature 2003. Debnath AK. Ding Y. 30. Mabery E. Garaud J-J et al. 23:430-437. Lancet 2004. Hostetler KY. Antiviral Res 2004. J Virol 2003. J Antimicrob Chemother 2004. inhibitor. 42. Arnold JJ. pestivirus antiviral compound. Hay A. Martina BE. Hartline C. Letellier C et al. Hayden FG. Hampson A. Crotty S. Li W. J Virol 2005. 426:450-454. Ramadori Current Opinion in Microbiology 2005.: Ribonucleoside analogue that blocks replication of bovine 46. Racela J. 23. epidemic. Klenk HD. McBrayer TR. Andino R. Sugaya N. interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Li Y. Diago M. 2:704-720. Paeshuyse J. 100:13190-13195. Moore MJ. Sui J. Hong Z. van Riel D. Gao M: anti-neuraminidase drugs (NAIs) in the community. Seipel M. Rizzetto M et al. Nat Rev Drug Discov 2002. identification of fusion inhibitors. Antiviral Res 2002. Stadler K. Rice CM.-S. Juan H-F. Tharnish PM. Farmar J. the viral RNA-dependent RNA polymerase. Specific inhibition of bovine viral diarrhea virus replicase. Mo L. 41. Wong SK. Proc Natl Acad Sci USA the SARS coronavirus. Beadle JR. Rose BC. DiCaro A.: 48. 22:423-427. Collett MS: Mechanism of action of a 2003. Huang H-C. Chu CK. Pang H et al. Lau JYN. Li W. vitro against flaviviruses and paramyxoviruses is mediated by 279:3197-3201. Greenough TC et al. 38. Morgan TR. Charlier N. Leyssen P. Trepo C. Zhong W.: Pegylated interferon-a protects type 1 pneumocytes against SARS coronavirus infection in macaques. Lancet 2004. Antimicrob Agents Chemother 2002. De Clercq E. St Clair Tallarico A. Aoki F. Trivedi T. McHutchison JG. Neyts J: The predominant acid fragment of the SARS coronavirus S protein efficiently mechanism by which ribavirin exerts its antiviral activity in binds angiotensin-converting enzyme 2. Microbiol 2004. et al.: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Zhou Z. current status and emerging strategies. If SARS re-emerges. Kerkhofs P. Nature 2003. Maag D. Wong M-H. Rationale for the use of cidofovir derivatives that could be administered perorally to control (prevent and treat) poxvirus infections. Shi J et al. et al. Nat Rev 21. Proc Natl Acad Sci USA 2004. Lindsay KL. 55:1-13. 363:938-947. Kuo C-J. Sonenberg N: Hepatitis C therapeutics: Drug Discov 2002. Escalante CR. Mitamura K. Bolger G. Cordingley MG study. Balzarini J. Masignani V. virus. Sun L. Fried MW. J Biol Chem 2004. Koenen F. Kuiken T. Sun SC. Marinos G. Nat Med 24. Kawaoka Y: Resistant influenza 26.: Adherence to combination therapy enhances sustained 40. Stuyver LJ. influenza epidemic. McKimm-Breschkin J. 364:759-765. A viruses in children treated with oseltamivir: descriptive Bonneau P. 189:1164-1167. De Clercq E: Cidofovir in the treatment of poxvirus infections. Recent highlights in the development of new antiviral drugs De Clercq 559 17. Smee DF. interferon inducers. Kawakami C. 8:552–560 . Nat Rev Microbiol 2003. Ann Intern Med 2004. 48:404-412. 33. Marcellin P. Patel K. Plummer F. www. 79:1943-1947. Lambkin R: A new millenium  conundrum: how to use a powerful class of influenza 28. to zanamivir and oseltamivir. Beadle JR. therapy in chronic hepatitis C: a randomized study of should be the drug of choice to prevent and/or control a new SARS treatment duration and ribavirin dose. Olurinde M. Luzuriaga K. de Jong T.. Siu J. 10:290-293. 2004. Kimura K. 35. Berne MA.: Interaction between heptad 19. Shi Y. Hadziyannis SJ. 101:2536-2541.: Small molecules targeting severe acute respiratory syndrome human 22. 77:6753-6760.: A novel highly selective inhibitor of pestivirus replication that targets 45. 347:975-982. van Amerongen G. Biotechnol 2004. Gonçales FL. Kern ER. Kiso M. 53:133-136. Bernstein D. Benetatos CA. Lamarre D. Bos M. Cartier M. now available for the treatment of chronic hepatitis C. Kinney RM. Choe H et al. Sidwell RW: Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Leyssen P. Proc Natl Acad Sci USA 2004. Liu S.E. Rappuoli R: SARS — beginning to understand a new 47. Haagmans BL.: Peginterferon-a2a and ribavirin combination pegylated IFN-a. 36. in the wake of any approved vaccine or treatment. 20. Paeshuyse J. 79:5116-5128.: Potent neutralization of severe acute respiratory syndrome 18. Paning M. Collins DJ. Cameron CE: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000. Kroeker AD. Diago M. Itamura S. Quenelle DC. Sullivan JL. Wong SK. Cheng Y. 6:1375-1379. 43. Antimicrob Agents Chemother Chunduru SK. Wan WB. and 62:A84-A85. Tien P et al. 37. 98:6895-6900. Trends blocks receptor association. He Y. Jordan R. viral diarrhea and hepatitis C viruses in culture. Boddeker N. Bailey KW. 34. Choe H. Lostia S. Rodriguez N. Baginski SG. 31. Lemm JA. Sun JH. Chan KH hepatitis C. Antimicrob Agents Chemother 2003. Strong JE. Oxford J.

is required to re-use any materials in Trends or Current Opinion journals or any other works published by Elsevier. 78:10617-10627. Paul J Am Chem Soc 2005. Princen K.: A induces massively increased interferon-a production in Mannose-specific plant lectins from the Amaryllidaceae Ebola virus-infected mice. 362:1953-1958. Balzarini J. Geisbert TW. Daeyaert F. Egberink H. of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003. Paul Janssen. Antimicrob Agents 52. Mol Pharmacol 55.  Busson R. De Clercq E. 127:5056-5065. phosphonates. Elsevier authors can obtain permission by completing the online form available through the Copyright Information section of Elsevier’s Author Gateway at http://authors.6- dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 56. Froeyen M. 53. pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis. Huggins JW: Treatment of lethal Ebola virus Deoxyribonucleoside (as well as ribonucleoside) phosphonates might infection in mice with a single dose of an S-adenosyl-L. Scroll down to the thumbnail of the required figure 4. de Jonge M. Janssen. Naesens L. Antiviral Res 2002. Vermeire K. Andrei G. Wang J. Locate the article with the required figure in the ScienceDirect journal collection 2. Balzarini J. Larsen T. Driscoll J. (R278474. 5. De Clercq E. Bolmstedt A. Vlasuk GP: Treatment of Ebola virus infection with a recombinant inhibitor 58. discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2. 45:135-147. Ying Y. 48:3858-3870. family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Place the cursor over the image and click to engage the ‘Enlarge Image’ option. (as well as HCV) infections. Current Opinion in Microbiology 2005. Paragas J. Open a blank slide in PowerPoint or other image-display program 7.4. Baker RO: 3-Deazaneplanocin De Clercq E. On a PC. Chemother 2004. Geisbert T.elsevier. Leyssen P. rilpivirine). Neyts J. Balzarini J. De Clercq E: New approaches toward anti-HIV chemotherapy. Alternatively. Right-click over the slide and select ‘paste’ (Mac users hit ‘Apple-V’ or select the ‘Edit-Paste’ pull-down option) Permission of the publisher. 8:552–560 www. What’s new in the anti-HIV chemotherapy field? An updated review on 59. Reuse of Current Opinion and Trends journal figures in multimedia presentations It’s easy to incorporate figures published in Trends or Current Opinion journals into your PowerPoint presentations or other image-display programs. Schols D: Marked 54. Van Laethem K. Froeyen M. Simply follow the steps below to augment your presentations or teaching materials with our fine figures! Herdewijn P: Deoxythreosyl Representative example of the unabated medicinal chemistry approach phosphonate nucleosides as selective anti-HIV agents. Pasquier E et al. Janssen PA. Peumans W. current anti-HIV drugs. Hatse S. represent a new approach for the therapy of HIV and hepatitis B virus homocysteine hydrolase inhibitor. Vermeire K. Bray M. Schols D: Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. Heeres J.: In search of diaminopyrimidines. 48:1901-1909. Rote WE. readers can access the request form through Elsevier’s main web site at http://www. Hensley LE. 57. Guillemont J. Lewi PJ. Peumans W et al. Perno C-F. Antiviral Res 2000. Pannecouque C. 67:1556-1565. 48:1297-1313.elsevier. Aquaro S. Vanden Mooter G.sciencedirect.: Antiviral potential of a new generation of acyclic nucleoside 60. Hatse S. 2005. Hocková D et al. Van Laethem K. De Clercq E: Emerging anti-HIV drugs. Jahrling PB. Young HA. Van Damme E. Vinkers locate/permissions.560 Antimicrobials 50. the 6-[2-(phosphonomethoxy)alkoxy]-2. De Clercq E. Peumans W. Nucleosides Nucleotides Nucleic Acids a novel anti-HIV drug: multidisciplinary coordination in the 2005. Kempeneers V. in press.  Koymans L. Balzarini J. Wu T. Click on the ‘Full text + links’ hyperlink 3. towards the development of the ‘cure’ for AIDS: the legacy of Dr. Fredeking TM. Expert Opin Emerg Drugs depletion of glycosylation sites in HIV-1 gp120 under selection 2005. Bolmstedt . Bray M. Arnold E. J Virol 2004. Geisbert JB. as a tribute to the late Dr. J Med Chem 2005. Snoeck R. Van Damme E. De Clercq E. Raymond JL. 55:151-159. Vandamme A-M. Elsevier. 51. Hatse S. 10:241-274.  J Med Chem 2005. Pannecouque C. right-click over the expanded image and select ‘Copy’ from pull-down menu (Mac users: hold left button down and then select the ‘Copy image’ option) 6.